Biomarker Assessment Through Comprehensive Genomic Profiling

As the number of relevant oncology biomarkers has increased over the last decade, so has the use of comprehensive genomic profiling (CGP) for molecular characterization of solid tumors. CGP allows for simultaneous assessment of thousands of variants across hundreds of genes, as well as evaluation of complex biomarkers such as homologous recombination deficiency (HRD), tumor mutation burden (TMB), and microsatellite instability (MSI). In this workshop, hear how one research laboratory is leveraging the Oncomine Comprehensive Assay Plus (OCA+) to perform CGP in-house. Additionally, see results from a multi-site study evaluating performance of OCA+ across several parameters.